Abstract
The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Current Pharmaceutical Biotechnology
Title: Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009)
Volume: 10 Issue: 8
Author(s): Leyre Zuniga and Begona Calvo
Affiliation:
Abstract: The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Export Options
About this article
Cite this article as:
Zuniga Leyre and Calvo Begona, Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009), Current Pharmaceutical Biotechnology 2009; 10 (8) . https://dx.doi.org/10.2174/138920109789978702
DOI https://dx.doi.org/10.2174/138920109789978702 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of Edg-Like LPA Receptor-Ligand Interactions
Current Pharmaceutical Design Legumes: A Healthy and Ecological Source of Flavonoids
Current Nutrition & Food Science Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism TRP Channels as Targets for Therapeutic Intervention in Obesity: Focus on TRPV1 and TRPM5
Current Topics in Medicinal Chemistry Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study
Current Vascular Pharmacology Eight-Year Follow-Up of an Initial Case with NF-κB Decoy Oligodeoxynucleotide Transfection After Coronary Stent Implantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pregnancy in Type 2 Diabetes Mellitus - Problems & Promises
Current Diabetes Reviews Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Current Diabetes Reviews COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety RNA-Loaded Chitosan Nanoparticles for Enhanced Growth, Immunostimulation and Disease Resistance in Fish
Current Nanoscience Blood Glucose Lowering Effect by an Extract from Aronia (<i>Aronia melanocarpa</i>) - A Pilot Intervention Study
Current Nutraceuticals Does Vitamin D Deficiency Epidemic Parallel with Allergy and Asthma Epidemic?
Mini-Reviews in Medicinal Chemistry The Frequency and Risk Factors of Diabetic Foot Ulcer Recurrence Among Jordanian Patients with Diabetes
Current Diabetes Reviews Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology Genetic and Epigenetic Regulation of Phosphoinositide 3-kinase Isoforms
Current Pharmaceutical Design Mechanisms of Endothelial Dysfunction and Cardiovascular System Adaptation
Current Vascular Pharmacology XBP-1 and the UPRosome: Mastering Secretory Cell Function
Current Immunology Reviews (Discontinued) Review of Electrochemical Technologies for Environmental Applications
Recent Patents on Engineering Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued)